Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32672056 | 1.00 | NOTUM (0.52) | NOTUMMEN1KMT2ATDP1CCNE1 | |
| SCHEMBL27785448 | 0.85 | KMT2A (0.47) | NOTUMMEN1KMT2ATDP1CCNE1 | |
| SCHEMBL2595570 | 0.83 | CCNE1 (0.47) | MEN1KMT2ATDP1CCNE1CDK2 | |
| SCHEMBL1011423 | 0.82 | ALDH1A1 (0.50) | MEN1KMT2ATDP1CCNE1CDK2 | |
| SCHEMBL31028805 | 0.82 | ALDH1A1 (0.50) | MEN1KMT2ATDP1CCNE1CDK2 | |
| SCHEMBL5788823 | 0.82 | RAB9A (0.58) | MEN1KMT2ACCNE1CDK2CDK5 | |
| SCHEMBL16775794 | 0.81 | RAB9A (0.49) | MEN1KMT2ATDP1CCNE1CDK2 | |
| SCHEMBL1009480 | 0.81 | CCNE1 (0.45) | MEN1KMT2ACCNE1CDK2CDK5 | |
| SCHEMBL18058629 | 0.81 | CCNE1 (0.48) | NOTUMMEN1KMT2ATDP1CCNE1 | |
| SCHEMBL32672176 | 0.80 | FAAH (0.45) | MEN1KMT2ATDP1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093244-B2 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093244-B2 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093244-B2 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| US-8044052-B2 | Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis | PFIZER INC. (US) | 2011-10-25 | — | — | US | disclosed |
| CN-102219784-A | Heteroaryl urea derivatives useful for inhibition of CHK1 | ICOS CORP | 2011-10-19 | — | — | CN | disclosed |
| CN-101151259-B | Heteroaryl urea derivatives useful for inhibition of CHK1 | ICOS CORP | 2011-06-15 | — | — | CN | disclosed |
| EP-2330105-A1 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS Corporation (US) | 2011-06-08 | — | — | EP | disclosed |
| EP-2330105-A1 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS Corporation (US) | 2011-06-08 | — | — | EP | disclosed |
| EP-2076508-B1 | BIARYL ETHER UREA COMPOUNDS | PFIZER PROD INC (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-1869020-B1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORP (US) | 2010-12-01 | — | — | EP | disclosed |
| WO-2007144579-A1 | N-OXIDES OF DIARYLUREA DERIVATIVES AND THEIR USE AS CHK1 INHIBITORS FOR THE TREATMENT OF CANCER | SENTINEL ONCOLOGY LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| US-7259166-B2 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1501815-B1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006105262-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl | ICOS CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
| US-7105671-B2 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20060178429-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | CORBETT WENDY L | 2006-08-10 | — | — | US | disclosed |
| EP-1501815-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003095438-A9 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-12-23 | — | — | WO | disclosed |
| US-20030225283-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | CORBETT WENDY LEA (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2003095438-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178429-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | GCKR, GCK, PDXK | NOTUM 627/4885MEN1 4537/4885KMT2A 3552/4885 |
| US-20030225283-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | GCKR, GCK, PDXK | NOTUM 627/4885MEN1 4537/4885KMT2A 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.